Report
Christophe-Raphaël Ganet

Novacyt : COVID: a historic gateway to a makeover

Novacyt appears to have benefited from the wave of COVID testing, with over 2000% in estimated revenue growth and adjusted EBITDA estimated at more than € 210me in vs € 0.2m at end-2019. In 2021, the DHSC contract in the UK and further screenings should enable the group to maintain its revenues and profits at a high plateau, with, however, a slowdown compared to 2020. The phenomenal cash generation tied to Sars-CoV-2 represent an opportunity to extend the group’s platform and tra...
Underlying
Novacyt SAS

Novacyt is an international diagnostics group. Co. sales clinical products used in oncology, microbiology, haematology and serology testing, focusing on the development, manufacture and commercialisation of molecular, protein and whole-cell diagnostic products. Co. also develops new products for the infectious disease and oncology testing markets. Co. operates it business through three divisions that are principally based in the United Kingdom with additional operations in France, China, Australia and the United States: Primerdesign, NOVAprep® and Lab21.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Christophe-Raphaël Ganet

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch